Wednesday, December 6, 2023
HomeHIV/AIDSLong-acting injectable ARVs are convenient and private

Long-acting injectable ARVs are convenient and private

HIV-positive people who took injectable cabotegravir + rilpivirine every four or eight weeks as antiretroviral therapy found it more convenient and discreet than daily pills, also feeling that it eliminated a “daily reminder of living with HIV”, Deanna Kerrigan and colleagues report. Similarly, HIV-negative men who took injectable cabotegravir every 12 weeks as pre-exposure prophylaxis (PrEP) felt that it was probably more convenient and easier to adhere to than daily pills, according to a study from the same research team.

Healthcare providers were also supportive, but did point out that the clinical management of long-acting injectable antiretrovirals (ARVs) is more complex. They noted that injectables will not necessarily eliminate the challenge of adherence, with regular attendance at clinic visits more crucial than ever.

Both studies involved in-depth interviews with subsets of people who had taken part in phase II clinical trials, as well as with healthcare providers at trial sites.

The LATTE-2 trial provided cabotegravir + rilpivirine to HIV-positive people who had not previously taken HIV treatment before, in the US and Spain. Injections occurred every four or eight weeks, depending on which study arm a person was randomised to. For the follow-up qualitative study, 27 study participants and 12 healthcare providers were interviewed.

The ÉCLAIR trial provided cabotegravir to HIV-negative men, as PrEP, in the US. Participants had injections every 12 weeks, although it has since become clear that an eight-week schedule is more likely to be effective. For the qualitative study, 26 participants and four healthcare providers were interviewed.

In both studies, most but not all of the trial participants interviewed were gay men in their thirties. As people who had volunteered to take part in these studies, they may be more motivated and enthusiastic about injections than other people who need ARVs. Also whereas by definition the HIV-positive participants all needed HIV treatment, most of the HIV-negative participants did not feel that they were at high enough risk to need to take PrEP for themselves.

Most trial participants had had some side-effects from the injections, typically soreness and minor bruising at the injection site for a day or two. A minority had more severe reactions such as fever or impaired mobility. Nonetheless, most felt that the side-effects were “worth it”, as this man taking cabotegravir + rilpivirine for HIV treatment explained: “One day is nothing… It’s as if you have a day with a headache. You take ibuprofen and that’s it. You put up with it. It’s temporary.”

Injections were felt to be more convenient and easier to adhere to than daily pills by both sets of participants. Especially among those living with HIV, injections were felt to be more private, as other people would not inadvertently see their medication.

“It seems to me that it’s much better because you simply don’t have to worry about anything. If you go on a trip, you don’t have to bring your pills or take anything at all along. You follow your ‘normal life.’ You come once a month. You get the shot and it’s over. You don’t have to be thinking everyday… oh I forgot to take the pill. Or… when did I take it last… You just don’t worry about anything. In reality, taking the pill everyday keeps it [HIV] present… and the shot is just once a month… You remember it when you come in and the rest of the time you can basically forget it.”

Nonetheless, a few participants did express concern about the number of clinic visits required. Friends, family and work colleagues could ask why the person needed to see the doctor so often, potentially leading to unwanted disclosure of HIV status.
Participants agreed that the intramuscular injections (in the buttocks) needed to be provided by a skilled professional, such as a doctor or nurse. A number of possible clinical settings were suggested for providing the injections, but self-injection was not felt to be realistic.

Gay men taking part in the PrEP trial often felt that the injection could give ‘peace of mind’, especially given unanticipated risks. “I’m thinking why not do injectable PrEP because there could be that one night where you’re not even planning for that, you’re like, oh wait, I have to take pills for a week before I even consider doing this. Because for men who have sex with men, being spontaneous is there. The hookup culture is so prevalent.”

When asked who are the ‘right people’ to use injectables – rather than daily pills – respondents often referred to people who find adherence challenging. Mention was made of people with unstable lives, homeless individuals, substance users and younger people. Potential users must also not have an aversion to needles. But most of the people living with HIV said that they would recommend injectables to ‘anyone’ living with HIV. Several said that their friends were jealous when they learned of how they were taking their medication. “90% of the people will prefer this method.”

However, the healthcare providers who were interviewed suggested that injections may not be right for everyone, with the choice of medication best decided on a case by case basis. While people who are less likely to adhere to daily pills might theoretically be good candidates for injectables, they noted that people still need to show up for appointments. “My concern with injections is this: when you have someone who's just not compliant. If they're not compliant and they miss two or three oral doses, it's not the end of the world. If you're not compliant with every eight weeks, that could be an issue. So you've got to get people who understand the importance of adhering.”

One older man living with HIV noted that as he needed to take several other oral medications in addition to his HIV treatment, he was happy to stick with the pills.

Clinicians also noted that the clinical management of injectables was more complex than with daily pills. Patients need to begin with oral drugs, then switch to injectables, a process which needs to be actively managed. Injectables cannot be discontinued quickly in the event of adverse reaction. Moreover, cabotegravir persists in the body for a long time after discontinuation, potentially creating problems in relation to drug resistance.

To conclude, both injectable HIV treatment and injectable PrEP were highly acceptable and feasible for study participants, with the potential to allow for better adherence.

Abstract 1
Challenges with adherence to daily oral antiretroviral therapy (ART) among people living with HIV (PLHIV) have stimulated development of injectable long-acting (LA) regimens. We conducted 39 in-depth interviews with participants and providers in a Phase IIb study (LATTE-2) evaluating an injectable LA regimen in the U.S. and Spain. Interviews exploring participant and provider attitudes and experiences with LA versus oral ART were audiotaped, transcribed and analyzed using thematic content analysis. Participants described the convenience of LA injections versus daily pills and emotional benefits such as minimized potential for HIV disclosure and eliminating the “daily reminder of living with HIV.” Providers recognized benefits but cautioned that LA candidates still need to adhere to clinic visits for injections and raised questions around ongoing clinical management. LA was seen as preferable to daily oral ART among PLHIV. Further research is needed regarding appropriate candidates, including with women and “non-adherent” populations across settings.

Deanna Kerrigan, Andrea Mantsios, Miguel Gorgolas, Maria-Luisa Montes, Federico Pulido, Cynthia Brinson, Jerome deVente, Gary J Richmond, Sarah W Beckham, Paige Hammond, David Margolis, Miranda Murray

Abstract 2
Adherence challenges with oral pre-exposure prophylaxis have stimulated interest in alternate modes of administration including long-acting injections. We conducted 30 in-depth interviews with 26 male trial participants and 4 clinical providers in a Phase IIa study (ÉCLAIR) evaluating the use of long-acting cabotegravir (CAB-LA) injections in New York and San Francisco. Interviews exploring attitudes and experiences with CAB-LA were audiotaped, transcribed, and analyzed using thematic content analysis. Despite a high frequency of some level of side effects, almost all participants reported being interested in continuing with CAB-LA, versus a daily oral, due to its convenience and the perceived advantage of not worrying about adhering to pills. Providers reinforced the importance of CAB-LA as a prevention option and the need for guidelines to assist patient decision-making. Further research is needed on the acceptability of CAB-LA among men and women at higher risk for HIV in different settings.

D Kerrigan, A Mantsios, R Grant, M Markowitz, P Defechereux, M La Mar, SW Beckham, P Hammond, D Margolis, M Murray

[link url=""]Aidsmap material[/link]
[link url=""]PLOS One abstract[/link]
[link url=""]Aids and Behaviour abstract[/link]

Subscribe to our Newsletter

Receive Medical Brief's free weekly e-newsletter.

* indicates required